Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: tonyt who wrote (27407)	1/14/1999 8:30:00 AM
From: Henry Niman	Respond to of 32384

Actually, since the SF warning as well as the CBS warning are linked, the reader can make an intelligent decision by just clicking and reading. The SF (venture capitalist Jean Deleage), CBS, and several CNBC (by Biotech and Pharmaceutical analysts) reports, all discuss Biotech funding and consolidation in general. I know of no current report that issues a warning about LGND funding. In fact one of the articles listed LGND as an acquirer (along with AMGN and CHIR), and CNBC did list several companies that were in the iffy category (including AMLN). The CNBC report indicated that there were about 350 public Biotechs and in the next two years that number was projected to fall into the 50-100 range.